Drug Profile
Research programme: protein misfolding disease therapeutics - Servier/Treventis Corporation
Alternative Names: TRV 101; TRV-1140; TRV-1387; TRV-217Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator TREVENTIS Corporation
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Huntington's disease; Parkinson's disease; Progressive supranuclear palsy
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Progressive-supranuclear-palsy in Canada (PO)
- 04 Jan 2018 Servier and Treventis Corporation agree co-develop compounds inhibiting tau and Ab proteins for Neurodegenerative disorders